16,637 PATIENTS TREATED AS OF 12/26/2025

TELL US YOUR STORY

camcevi
Search...
Search...

CAMCEVI® is a registered trademark of Foresee Pharmaceuticals, Co LTD. used under a license with Accord BioPharma, Inc. Accord BioPharma, and associated logos are trademarks of Accord BioPharma. All other trademarks are property of respective owners. ©2026 Accord BioPharma. All rights reserved. This content is intended for U.S. audiences only. WSB-CAM-2400004

Welcome to Camcevi

Patients Treated1
Data estimation as of 12/26/2025.
A number worth celebrating
16,000+1
Men have been treated with camcevi®
The fastest growing 6-month ADT2
References: 1. Accord BioPharma. Data on file.
2024. 2. Accord BioPharma. Data on file. 2024.

UNDERSTANDING YOUR PLAN

Shot-family-pic

Whether you have been living with advanced prostate cancer for a while or are newly diagnosed, it’s important to know that there are treatment options. Your healthcare professional will work with you on your treatment plan, which may now include CAMCEVI®.

Learn how
CAMCEVI BOX & SYRINGE
ABOUT CAMCEVI

ABOUT
CAMCEVI

Understand how CAMCEVI works to manage advanced prostate cancer.

Learn more
GETTING STARTED

GETTING
STARTED

Know what to expect with your CAMCEVI treatment.

Learn more
SUPPORT & RESOURCES

SUPPORT +
RESOURCES

Find additional resources and education for living with advanced prostate cancer.

Learn more

FAST FACTS

Prostate cancer is the second most common cancer in American men, after skin cancer1

About 6 in 10 men
with prostate cancer are
age 66 or older1

African American men and Caribbean men of African descent have a greater risk of prostate cancer2

Prostate cancer is grouped into four stages, with stages III and IV representing advanced prostate cancer3

IMPORTANT SAFETY INFORMATION

What is CAMCEVI®? CAMCEVI is an androgen deprivation therapy (ADT) used for treatment of adult patients with advanced prostate cancer.

You should not take CAMCEVI if you have ever had an allergic reaction to any of the ingredients in CAMCEVI or to any other medications called gonadotropin-releasing hormone (GnRH) agonists.

CAMCEVI may:

cause an increase in your testosterone level during the initial few weeks of treatment, which may cause temporary worsening of symptoms or additional signs and symptoms of prostate cancer. You may experience a temporary increase in bone pain. You may have trouble with urination or develop abnormal amount of pressure on your spinal cord which can result in paralysis, which may be life-threatening.

cause your blood sugar to increase, including increasing your risk of developing diabetes. You should have your blood sugar monitored while taking CAMCEVI.

increase your risk of heart problems including heart attack, sudden death, or stroke. It can also cause your heart to beat irregularly.

cause some patients to have seizures.

in rare cases, cause delayed serious skin reactions in patients receiving leuprolide-containing therapy. Immediately contact your doctor if you develop fever, flu-like symptoms, mucosal lesions, progressive skin rash, or swollen lymph nodes.

cause fetal harm if administered to a pregnant woman.

cause impotence and impair fertility in males of reproductive potential.

The most common side effects of CAMCEVI include hot flush, high blood pressure, reaction where you received your shot which may cause temporary burning/stinging, pain, bruising or redness, upper respiratory tract infections, muscle and bone pain, tiredness, and pain in extremity. Tell your healthcare provider if you experience a rash or severe injection site reaction.

For more information, talk to your healthcare provider.

These are not all the possible side effects of CAMCEVI. For additional information, see the full prescribing information or ask your healthcare professional or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA at 1-800-FDA-1088 or visit
fda.gov/medwatch.

Click here for full Prescribing Information.

References:

1. American Cancer Society. About Prostate Cancer. Revised January 2022. Accessed January 19, 2022. https://www.cancer.org/content/dam/CRC/PDF/Public/8793.00.pdf 2. American Cancer Society. Prostate Cancer Causes, Risk Factors, and Prevention. Revised June 2020. Accessed January 19, 2022. https://www.cancer.org/content/dam/CRC/PDF/ Public/8794.00.pdf 3. Urology Care Foundation. American Urological Association. Accessed February 15, 2022. https://www.urologyhealth.org/urology-a-z/a_/advanced-prostate-cancer